


AMENDMENTS TO THE CLAIMS

Please cancel claims 1-20 and 32-53, amend claim 21, and add new claims 54-56, as follows:

Claims 1-20 (Cancelled).

Claim 21 (Currently Amended) A liposomal composition comprising:  
a glycoside exhibiting antitumor activity, wherein said glycoside is represented by a  
compound of formula (1):



a phospholipid; and

a positive-charge-providing substance,

wherein G represents a sugar moiety selected from the group consisting of  
GlcNAc-Gal-, GlcNAc-Gal-Glc-, and Fuc-Gal-, and Gal-Glc-, and Gal-,

wherein said phospholipid and said positive-charge-providing substance are capable  
of forming a liposome.

Claim 22 (Previously Presented) The liposomal composition according to claim 21,  
wherein said phospholipid is selected from the group consisting of phosphatidylcholines,  
phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid.

Claim 23 (Previously Presented) The liposomal composition according to claim 22, wherein said phospholipid is a phosphatidylcholine selected from the group consisting of dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dilinoleoylphosphatidylcholine, myristoylpalmitoylphosphatidylcholine, myristoylstearylphosphatidylcholine, and palmitoylarachidoylphosphatidylcholine.

Claim 24 (Previously Presented) The liposomal composition according to claim 23, wherein said phosphatidylcholine is dipalmitoylphosphatidylcholine.

Claim 25 (Previously Presented) The liposomal composition according to claim 21, wherein said positive-charge-providing substance is an aliphatic amine.

Claim 26 (Previously Presented) The liposomal composition according to claim 25, wherein said aliphatic amine is stearylamine.

Claim 27 (Previously Presented) The liposomal composition according to claim 25, wherein said aliphatic amine is oleylamine.

Claim 28 (Previously Presented) The liposomal composition according to claim 21, wherein said positive-charge-providing substance is an aromatic amine.

Claim 29 (Previously Presented) The liposomal composition according to claim 28, wherein said aromatic amine is fluoreneethylamine.

Claim 30 (Previously Presented) An anticancer agent comprising:  
  
the liposomal composition according to claim 21; and  
  
one or more pharmaceutically acceptable additives selected from the group consisting of excipients, carriers, binders, disintegrating agents, lubricants, humectants, colorants, flavorants, deodorants, preservatives, stabilizers, pH adjusters, buffers, isotonicity-imparting agents, water, surfactants, and anesthetic agents.

Claim 31 (Previously Presented) The anticancer agent according to claim 30, wherein said anticancer agent is formulated in a dosage form selected from the group consisting of a peroral solid, a peroral liquid, an injection, a suppository, an ointment, and a patch.

Claims 32-53 (Cancelled).

Claim 54 (New) The liposomal composition according to claim 21, wherein said G represents a GlcNAc-Gal- sugar moiety.

Claim 55 (New) The liposomal composition according to claim 21, wherein said G represents a GlcNAc-Gal-Glc- sugar moiety.

Claim 56 (New) The liposomal composition according to claim 21, wherein said G represents a Fuc-Gal- sugar moiety.